Navidea Biopharmaceuticals Inc., of Dublin, Ohio, said the Journal of Nuclear Medicine published the results from a clinical trial of NAV4694 in healthy subjects and those with diagnosed forms of dementia

AG014 comprises oral delivery of an anti-TNF antibody with proven clinical efficacy in IBD, resulting in local efficacy and an improved safety profile over systemic drugs...Shares of Northwest (NASDAQ:NWBO) fell 13 cents to close Thursday at $3.77.

Alkermes Inc., of Dublin, Ireland, said top-line data from a Phase II study showed that ALKS 5461, a drug in development to treat patients who have an inadequate response to standard therapies for clinical depression, significantly reduced depressive symptoms across a range of standard measures, including the study's primary outcome measure, the Hamilton Depression Rating Scale (p = 0.026), the Montgomery-Asberg Depression Scale (p = 0.004) and the Clinical Global Impression-Severity Scale (p

Proceeds will be used to advance its gene therapy product for congestive heart failure into clinical development...BofA Merrill Lynch, Barclays and Leerink Swann acted as joint book-running managers, while Stifel and Piper Jaffray served as co-managers. (See BioWorld Today, April 2, 2013.)

clinical trials, for SMD and dry age-related macular degeneration (dry AMD...BHR Pharma LLC, of Herndon, Va., said the 1,000th patient has been enrolled in its SyNAPSe clinical trial, a global Phase III study evaluating the effectiveness of its intravenous progesterone infusion agent, BHR-100, to treat severe traumatic brain injury (TBI...NeuroDerm Ltd., of Ness Ziona, Israel, said enrollment of patients is ongoing in its Phase IIa clinical trial of ND0612, a treatment for Parkinson's disease

Coronado plans to use the proceeds to fund R&D, clinical trials and manufacture of supply as well as other corporate purposes

The study was carried out to explore previous clinical findings with cabozantinib in castration-resistant prostate cancer patients with bone metastases showing a 67 percent rate of bone scan response and other clinical signs of effect

Regentis raised $10 million last year in a Series C financing to support clinical studies and commercial launch of GelrinC in Europe. (See BioWorld Today, May 15, 2012

RP5063 also showed efficacy in the Clinical Global Impression Severity Scale and was well tolerated...The study, designated TRIG-05, is set to start enrollment this month, with a primary clinical endpoint of demonstrating efficacy, tolerability and safety...Viralytics Ltd., of Sydney, Australia, said it finalized the clinical study report on the Phase I evaluation of Cavatak, administered intravenously to late-stage melanoma, prostate, breast or colorectal cancer patients, with results showing that

The company's "exceptional team" and its potential to obtain rapid clinical efficacy data were two attractive attributes, Rafaèle Tordjman, managing partner at Sofinnova Partners, told BioWorld Today...The company plans to use the funds to move its lead program into clinical trials and to advance a second discovery program...On Tuesday, shares of StemCells (NASDAQ:STEM) gained 7 cents, closing at $1.68.

Canbex, a spinout of University College London, has said it expects to start clinical testing this year

The primary endpoint of the study is the induction of clinical remission at week 12...The study is being conducted by more than 60 clinical investigators worldwide, including about 11 sites in Brazil and 24 sites in India...The TRIG-05 study is expected to begin enrollment this month, with a primary clinical endpoint of demonstrating efficacy, tolerability and safety of TI-001

biotech to file for an initial public offering (IPO) this year, taking advantage of the emerging growth company provision in the Jumpstart Our Business Start-ups Act and aiming to raise as much as $86.3 million to support clinical work in multiple sclerosis, inflammatory bowel disease (IBD) and allergic/immune-mediate disorders...Funds will be used to progress the clinical development program for lead candidate, Pracinostat, its oral histone deacetylase inhibitor for advanced hematologic

Array BioPharma Inc., of Boulder, Colo., reported clinical data at the International Myeloma Workshop in Kyoto, Japan, showing that ARRY-520, a selective KSP inhibitor, demonstrated single-agent activity in heavily pretreated patients with relapsed or refractory multiple myeloma, with 19 months median overall survival and a 16 percent overall response rate

Net proceeds will be used to cover costs related to the new drug application for CompleoTRT, making a milestone payment for CompleoTRT, manufacturing scale-up for CompleoTRT and Tefina clinical trials

Novavax Inc., of Rockville, Md., said top-line data from its Phase II dose-ranging study testing its respiratory syncytial virus (RSV) vaccine candidate in women of childbearing age hit its protocol-specified objectives, supporting progression to the next stage of advanced clinical testing

Eyeing Better Mousetrap with Topical Product In 2009, Revance granted worldwide aesthetic and dermatological rights to RT002, then in preclinical studies, to Medicis Pharmaceutical Corp., of Scottsdale, Ariz., in exchange for $10 million at signing and another potential $94 million, based on clinical, regulatory and commercial milestones...The latest round is expected to support ongoing clinical development of lead candidate, LiRIS (lidocaine releasing intravesical system), in development for

Tengion Inc., of Winston-Salem, N.C., said the firm's clinical trial application was accepted in Sweden to start a Phase I trial testing its Neo-Kidney Augment in up to five patients with advanced chronic kidney disease

Net proceeds totaled $12 million and will be used to fund R&D and clinical trials, acquisition of intellectual property and other purposes...The funds will be used to advance Theraclone's clinical programs and support its I-STAR technology platform.